Categories
Change Password!
Reset Password!
FDA approves the ‘first-ever’ oral therapy for eos...
First Time for 10 Years AAAAI Changes Guidelines f...
Atopic dermatitis (AD) is the most common skin illness, with a prevalence of up to 20.1% in children and 2.1% to 4.9% in adults. AD is characteri...
Sublingual immunotherapy displays noteworthy effic...
Often overlooked in treatment studies, epistaxis (commonly known as nosebleeds) is a common issue among allergic rhinitis (AR) patients. This ret...
Abrocitinib 100mg predicts week 12 success in atop...
Research in 'Dermatology and Therapy' aimed to predict the early efficacy of Abrocitinib in atopic dermatitis, suggesting potential for e...
Benralizumab: Promising results for eosinophilic a...
According to a recent post-hoc analysis of the ANANKE trial published in the Dovepress- Journal of Asthma and Allergy, the use of Benralizumab th...
Remineralizing roots: A study on toothpastes for a...
Innovative toothpastes with biomimetic and re-mineralising properties have been shown to have great potential against enamel demineralisation as...
Variations in chronic inducible urticaria: subtype...
CInducibleU is a kind of chronic urticaria (hives) triggered by specific factors. It can occur alone or alongside chronic spontaneous urticaria (...
Rapidly improved patient-reported outcomes with th...
The integrated data from the two clinical trials suggested that Upadacitinib monotherapy rapidly and effectively improved patient-reported outcom...
Omalizumab proves to be effective in treating food...
Food allergies, a growing concern with significant health impacts, currently have limited treatment options. A recent study in ‘The New Eng...
Annual Allergen of the Year Award
To highlight allergens with significant clinical impact, bring awareness to under-recognized agents, and acknowledge those that have become outda...
